Medidata has launched Medidata Plus, a clinical artificial intelligence layer that unlocks the full breadth of AI capabilities across the Medidata Platform. The solution claims to integrate AI across every stage of clinicaltrials, providing a unified platform that streamlines study design, data management, and real-time risk monitoring to accelerate execution and deliver actionable insights.
“Stitching together point solutions isn’t a strategy — it’s a liability. Drug development’s next leap will come when AI is consistent, connected, and portfolio-wide,” said Dr Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology, IDC. “Medidata Plus delivers this with a cohesive AI layer across the entire lifecycle, shifting organisations from sporadic AI adoption to a continuous, portfolio-wide strategy that drives real clinical outcomes.”
Medidata Plus
Key capabilities of yje Medidata Plus include:
- Faster Study Builds: AI cuts study setup from weeks to hours by automating EDC and eCOA design and generating synthetic patient data for testing.
- No-Code Data Integration: Seamlessly ingests, standardises, and transforms clinical and real-world data without coding.
- Proactive Risk Detection: Real-time analytics identify enrollment and safety issues early, reducing delays and supporting faster inspections.
- AI-Powered Audit Insights: Natural-language queries enable study teams to quickly explore audit histories and uncover regulatory insights.
“We’ve listened to our customers, and they’re clear that AI can transform clinical trials, but not as an army of agents from disparate sources trained in disparate ways,” said Anthony Costello, CEO, Medidata. “Medidata Plus is a drop-in AI strategy for clinical research that upskills teams, automates workflows, and surfaces insights at a pace that’s redefining what teams thought was possible. We are in conversations with dozens of customers about making this shift, and what we’re hearing tells us the industry has been waiting for exactly this.”
